黄灿华

发布时间:2022-01-19      作者:学院办公室      审核:      编辑:      点击:
审核人

黄灿华:四川大学华西医院生物治疗国家重点实验室教授,博士生导师

【简历】

2000年在中国科学院获博士学位,随后在新加坡国立大学生物系从事博士后研究;2003年8月被新加坡国立大学肿瘤研究所聘为Research Scientist。2005年9月回国任四川大学生物治疗国家重点实验室教授;四川大学华西基础医学与法医学院院长(2017-2021)。国家杰出青年科学基金获得者(2012);国家重大科学研究计划(973计划) “病毒诱导肿瘤发生的氧化还原蛋白质组研究”项目首席科学家(2013-2017);国家自然科学基金委“氧化还原信号调控与肿瘤发生发展”创新群体项目负责人(2018);科技部“创新人才推进计划”重点领域创新团队负责人暨中组部第四批国家“万人计划”科技创新领军人才;国务院学位委员会第八届学科评议组(基础医学组)成员(2020);爱思唯尔中国高被引学者(2020,2021);教育部自然科学奖一等奖获得者(2020);中国生物化学与分子生物学会常务理事暨四川省生物化学与分子生物学会理事长;四川省政协委员;四川党外建言献策专家库专家成员;成都统一战线“同心智库”专家成员;成都市欧美同学会副秘书长;成都海外联谊会常务理事;享受国务院特殊津贴专家(2018)。

以通讯作者在 Nat Microbiol、Nat Commun、Cell Rep、Gastroenterology、J Hepatol、Hepatology、EMBO Mol Med、Cancer Res、Mol Cancer、Autophagy、Small、Cell Death Differ、Oncogene、Mol Cell Proteomics 等国际学术刊物出版论文90余篇。受邀请在 Trends Biochem Sci、Signal Transduct Target Ther、Semin Cancer Biol、Drug Resist Updat、J Hematol Oncol、Mass Spectrom Rev、Antioxid Redox Signal、Med Res Rev、Biochim Biophys Acta Rev Cancer 等国际学术刊物上发表多篇关于系统生物学前沿综述。国际学术刊物 MedComm 副主编, Antioxidants 顾问编辑, Anal Biochem 执行主编,Signal Transduct Target Ther、Proteomics 等编委委员。

【研究方向】

(1)氧化还原信号调控与肿瘤发生发展

(2)病毒诱发癌变的分子机理

【联系方式】

邮箱:hcanhua@hotmail.com(常用); hcanhua@scu.edu.cn

电话:+86-13258370346

实验室主页:黄灿华教授实验室

国重主页:黄灿华-生物治疗国家重点实验室

【代表性论著】(*为通讯作者)

1. Jiang J, Chen H, Jin P, Zhou L, Peng L, Huang Z, Qin S, Li B, Ming H, Luo M, Xie N, Gao W, Nice EC, Yu Q, Wei Y, Huang C*. Targeting PSAT1 to mitigate metastasis in tumors with p53-72pro variant. Signal Transduct Target Ther. In press.

2. Shi J, Tian H, Peng L, Huang C, Nice EC, Zou B, Zhang H*. A nanoplatform reshaping intracellular osmolarity and redox homeostasis against colorectal cancer.J Control Release. 2022;352:766-775.

3. Jia W, Tian H, Jiang J, Zhou L, Li L, Luo M, Ding N, Nice EC, Huang C*, Zhang H*. Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma. Small. 2022;e2205354.

4. Jin P, Jiang J, Zhou L, Huang Z, Qin S, Chen HN, Peng L, Zhang Z, Li B, Luo M, Zhang T, Ming H, Ding N, Li L, Xie N, Gao W, Zhang W, Nice EC, Wei Y, Huang C*. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis. EMBO Mol Med. 2022:e16082.

5. Lu S, Tian H, Li L, Li B, Yang M, Zhou L, Jiang H, Li Q, Wang W, Nice EC, Xie N*, Huang C*, Liu L*. Nanoengineering A Zeolitic Imidazolate Framework-8 Capable of Manipulating Energy Metabolism Against Cancer Chemo-Phototherapy Resistance. Small. 2022:e2204926.

6. Zhou L, Jiang J, Huang Z, Jin P, Peng L, Luo M, Zhang Z, Chen Y, Xie N, Gao W, Nice EC, Li J*, Chen H*, Huang C*. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA. Mol Cancer. 2022;21(1):168.  

7. Duan J, Huang Z, Nice EC, Xie N*, Chen M*, Huang C*. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res. 2022:S2090-1232(22)00188-6.

8. Tian H, Zhang T, Qin S ,Huang Z, Zhou L, Shi J, Nice EC, Xie N, Huang C*, Shen Z* . Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.

9. Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C*, Fu L*. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15,97.

10. Tian H, Zhou L, Wang Y, Nice EC, Huang C*, Zhang H*. A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis. J Control Release. 2022;348:590-600.

11. Qin S, Li B, Ming H, Nice EC, Zou B*, Huang C*. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. Biochim Biophys Acta Rev Cancer. 2022;1877(4):188749.

12. Huang Z, Zhang Z, Zhou C*, Liu L*, Huang C*. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm. 2022;3(2):e144.

13. Fan Q, Zuo J, Tian H, Huang C, Nice EC, Shi Z*, Kong Q*. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells. J Exp Clin Canc Res. 2022;41(1):1-17.

14. Peng L, Jiang J, Zhou L, Nice EC, Huang C*. A cellular thermal shift assay for detecting amino acid sites involved in drug target engagement. STAR Protoc. 2022;101423.

15. Zuo J, Zhang Z, Luo M, Zhou L, Nice EC, Zhang W, Wang C*,Huang C*. Redox signaling at the crossroads of human health and disease. MedComm. doi:110.1002/mco2.127.

16. Zhou L, Zhang Z, Nice EC, Huang C*, Zhang W*, Tang Y*. Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. J Hematol Oncol. 2022;15(1):21.

17. Zuo J, Zhang Z, Li M, Yang Y, Zheng B, Wang P*, Huang C*, Zhou S*. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. Mol Cancer. 2022;21(1):30.

18. Weng N, Qin S, Liu J, Huang X, Jiang J, Zhou L, Zhang Z, Xie N, Wang K, Jin P, Luo M, Peng L, Nice EC, Goel A, Han S*, Huang C*, Zhu Q*. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharm Sin B. doi:10.1016/j.apsb.2022.01.018.

19. Luo M, Huang Z, Yang X, Chen Y, Jiang J, Zhang L, Zhou L, Qin S, Jin P, Fu S, Peng L, Li B, Fang Y, Pu W, Gong Y, Liu Y, Ren Z, Liu QL, Wang C, Xiao F, He D, Zhang H, Li C, Xu H, Dai L, Peng Y, Zhou ZG, Huang C*, Chen HN*. PHLDB2 mediates cetuximab resistance via interacting with EGFR in latent metastasis of colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021;S2352-345X(21)00261-7.

20. Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, Zuo J, Zhang J, Mizokami A, Nice EC, Chen H*, Huang C*, Wei X*. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. doi:10.15252/emmm.202114903‍.

21. Yang M, Zhang Z, Nice EC, Wang C*, Zhang W*, Huang C*. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer. 2021;1877(1):188665.

22. Peng L, Jiang J, Chen H, Zhou L, Huang Z, Qin S, Jin P, Luo M, Li B, Shi J, Xie N, Deng L, Liou Y, Nice EC, Huang C*, Wei Y. Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. Cell Rep. 2021;37(9):110069.

23. Wang Z, Guo K, Liu Y, Huang C*, Wu M*. Dynamic impact of virome on colitis and colorectal cancer: immunity, inflammation, prevention and treatment. Semin Cancer Biol. 2021;S1044-579X(21):00254-6.

24. Zheng X, Liu R, Zhou C, Yu H, Luo W, Zhu J, Liu J, Zhang Z, Xie N, Peng X, Xu X, Cheng L, Yuan Q, Huang C*, Zhou X*. ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer. Cancer Res. 2021;81(24):6157-6170.

25. Peng L, Yin HY*, Huang C*. CNMa-CNMa receptor at microbiome-gut-brain axis: novel target to regulate feeding decision. Signal Transduct Target Ther. 2021;6(1):283.

26. Luo M, Yang X, Chen HN, Nice EC*, Huang C*. Drug resistance in colorectal cancer: An epigenetic overview. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188623.

27. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu S, Huang C*, Tang Y*. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021; 6(1):16.

28. Liu J, Huang Z, Chen HN, Qin S, Chen Y, Jiang J, Zhang Z, Luo M, Ye Q, Xie N, Zhou Z, Wei Y, Xie K*, Huang C*. ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-β axis in colorectal cancer. Oncogene. 2021; 40(19):3394-407.

29. Ming H, Li B, Zhou L, Goel A*, Huang C*. Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188519.

30. Xie N, Zhang L, Gao W, Huang C, Huber PE, Zhou X, Li C*, Shen G*, Zou B*. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020; 5(1):227.

31. Qin S, Jiang J, Lu Y, Nice EC, Huang C*, Zhang J*, He W*. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther. 2020; 5(1):228.

32. Li B, Jiang J, Assaraf YG, Xiao H, Chen Z-S*, Huang C*. Surmounting Cancer Drug Resistance: New Insights from the perspective of N6-Methyladenosine RNA Modification. Drug Resist Updat. 2020; 53:100720.

33. Jiang J, Peng L, Wang K*, Huang C*. Moonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code. Antioxid Redox Signal. 2020; 34(13):979-1003.

34. Zhang Z, Zhou L, Xie N, Nice EC, Zhang T*, Cui Y-P*, Huang C*. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020; 5(1):113.

35. Huang Z, Zhou J-K, Peng Y, He W*, Huang C*. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77.

36. Huang Z, Zhou J-K, Wang K, Chen H-N, Qin S, Liu J, Luo M, Chen Y, Jiang J, Zhou L, Zhu L, He J, Li J, Pu W, Gong Y, Li J, Ye Q, Dong D, Hu H, Zhou Z, Dai L, Wei Y, Huang C*, Wei X*, Peng Y*. PDLIM1 inhibits tumor metastasis through activating Hippo signaling in hepatocellular carcinoma. Hepatology. 2020; 71(5):1643-59.

37. Zhang Z, Gao W, Zhou L, Chen Y, Qin S, Zhang L, Liu J, He Y, Lei Y, Chen H-N, Han J, Zhou Z-G, Nice EC, Li C, Huang C*, Wei X*. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy. Theranostics. 2019; 9(17):4878-92.

38. Jiang J, Zhang L, Chen H-N, Lei Y, Zhang T, Wang Y, Jin P, Lan J, Zhou L, Huang Z, Li B, Liu Y, Gao W, Xie K, Zhou L, Nice EC, Peng Y, Cao Y, Wei Y, Wang K*, Huang C*. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy. 2020; 16(1):106-22.

39. Chen H-N, Chen Y, Zhou Z-G, Wei YQ, Huang C*. A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. Autophagy. 2019; 15(4):733-4.

40. Zhou L, Gao W, Wang K, Huang Z, Zhang L, Zhang Z, Zhou J, Nice EC, Huang C*. Brefeldin A Inhibits Colorectal Cancer Growth by Triggering Bip/Akt-regulated Autophagy. FASEB J. 2019; 33(4):5520-34.

41. Wang K, Jiang J, Lei Y, Zhou S, Wei Y, Huang C*. Targeting Metabolic-redox Circuits for Cancer Therapy. Trends Biochem Sci. 2019; 44(5):401-14.

42. Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y*, Huang C*. Redox signaling and unfolded protein response coordinate cell fate decisions under ER stress. Redox Biol. 2019; 25:101047.

43. Chen Y, Chen H-N, Wang K, Zhang L, Huang Z, Liu JY, Zhang Z, Luo MC, Lei YL, Peng Y, Zhou Z-G, Wei YQ, Huang C*. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol. 2019; 70(1):66-77.

44. Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H, Liu X, Zhou S, Lu XC, Yang HB, Xu C, Gao W, Zhou L, Wang YP, Hu W, Wei Y, Huang C*, Lei QY*. Nuclear Lactate Dehydrogenase A Senses ROS to Produceα-Hydroxybutyrate for HPV-induced Cervical Tumor Growth. Nat Commun. 2018; 9(1):4429.

45. Wang K, Zhang T, Lei Y, Li X, Jiang J, Lan J, Liu Y, Chen H-N, Gao W, Xie N, Chen Q, Zhu X, Liu X, Xie K, Nice EC, Wu M*, Huang C*, Wei Y. Identification of Annexin A2 as a Specific Bleomycin Target to Induce Pulmonary Fibrosis by Impeding TFEB-mediated Autophagic Flux. Autophagy. 2018; 29:1-14.

46. Wang K, Gao W, Dou Q, Chen H-N, Li Q, Nice EC, Huang C*. Ivermectin Induces PAK1-mediated Cytostatic Autophagy in Breast Cancer. Autophagy. 2016; 12(12)2498-9.

47. Dou Q, Chen H-N, Wang K, Yuan K, Lei Y, Li K, Lan J, Chen Y, Huang Z, Xie N, Zhang L, Xiang R, Nice EC, Wei Y and Huang C*. Ivermectin induces cytostatic autophagy by blocking PAK1/Akt axis in breast cancer. Cancer Res. 2016; 76(15):4457-69.

48. Li X, He S, Li R, Zhou X, Zhang S, Yu M, YeY, Wang Y, Huang C*, Wu M*. Pseudomonas aeruginosa infection augments inflammation through miR-301b repression of c-Myb-mediated immune activation and infiltration. Nat Microbiol. 2016; 1(10):16132.

49. Xie N, Yuan K, Zhou L, Wang K, Chen H-N, Lei Y, Lan J, Pu Q, Gao W, Zhang L, Shen G, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H*, Yang J* and Huang C*. PRKAA1/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy. 2016; 12(9):1507-20.

50. Chen H-N, Yuan K, Xie N, Wang K, Huang Z, Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG*, Huang C*. PDLIM1 stabilizes the E-cadherin/Beta-catenin complex to prevent epithelial-mesenchymal transition and metastatic potential of colorectal cancer cells. Cancer Res. 2016; 76(5):1122-34.

51. Yuan K, Lei Y, Chen H-N, Chen Y, Zhang T, Li K, Xie N, Wang K, Feng X, Pu Q, Yang W, Wu Min, Xiang R, Feitelson MA, Nice EC, Wei Y, Huang C*. HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 2016; 616–27.

52. Li X, He S, Zhou X, Ye Y, Tan S, Zhang S, Li R, Yu M, Jundt MC, Hidebrand A, Wang Y, Li G*, Huang C*, Wu M*. Lyn delivers bacteria to lysosomes for eradication through TLR2-initiated autophagy related phagocytosis. PLoS Pathog. 2016; 12(1):e1005363.

53. Lei Y, Wang K, Deng L, Chen Y, Nice EC, Huang C*. Redox Regulation of Inflammation: Old Elements, a New Story. Med Res Rev. 2015; 35(2):306-40.

54. Liu R, Li J, Zhang T, Zou L, Chen Y, Wang K, Lei Y, Yuan K, Li Y, Lan J, Cheng L, Xie N, Xiang R, Nice EC, Huang C*, Wei Y. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: Involvement of abnormal cholesterol trafficking. Autophagy. 2014; 10(7):1241-55.

55. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, Wu M, Nice EC, Huang C*, Wei Y. FGFR4 promotes stroma-induced epithelial to mesenchymal transition in colorectal cancer. Cancer Res. 2013; 73(19):5926-35. (封面论文).

56. Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C*, Wu M*. Decreased Levels of miR-224 and the Passenger Strand of miR-221 Increase MBD2, Suppressing Maspin and Promoting Tumor Growth and Metastasis in Mice. Gastroenterology. 2013; 145(4):853-64.e9.

57. Zhou S, Liu R, Yuan K, Yi T, Zhao X, Huang C*, Wei Y. Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. Mass Spectrom Rev. 2013; 32(4):267-311.

58. Zhou S, Yi T, Liu R, Bian C, Qi X, He X, Wang K, Li J, Zhao X*, Huang C*, Wei Y. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics. 2012; 11(7):M112.017988.

59. Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N, Shan Nai H, Wu H, Zhao X, Dong Q, Nice E, Huang C*, Wei Y. Proteomics identification of ITGB3 as a key regulator in ROS-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics. 2011; 10(10):M110.005397.

60. Wang K, Liu R, Li J, Mao J, Xie N, Wu J, Lei Y, Zhang T, Zeng J, Wu H, Chen L, Huang C.* Wei Y. Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy. 2011; 7(9):966-78.

61. Li J, Liu R, Lei Y, Wang K, Lau Q.C, Xie N, Zhou S, Nie C, Chen L, Wei Y, and Huang C*. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010; 6(6) :711-24.

62. Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, Zeng D, Tong A, Chen L, Wei Y, Huang C*. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer. 2010; 9:81.

63. Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, Chen L, Liang S, Zhao Y, Wei Y, Huang C*. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 2009; 8(1):70-85.

64. Li Z, Zhao X*, Bai S, Wang Z, Chen L, Wei Y, Huang C*. Proteomic identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics. 2008; 7(10):1810-23.

65. Wang Z, Jiang L, Huang C*, Li Z, Tong A, Chen L, Shen J, Gao F, Chen Q*. Comparative proteomic approach to screening of potential diagnostic and therapeutic targets for Oral Squamous Cell Carcinoma. Mol Cell Proteomics. 2008; 7:1639–50.

 

关闭